Eissler N - Search Results

1

PPM1D Is a Therapeutic Target in Childhood Neural Tumors.

Milosevic J, Treis D, Fransson S, Gallo-Oller G, Sveinbjörnsson B, Eissler N, Tanino K, Sakaguchi K, Martinsson T, Wickström M, Kogner P, Johnsen JI. Milosevic J, et al. Among authors: eissler n. Cancers (Basel). 2021 Nov 30;13(23):6042. doi: 10.3390/cancers13236042. Cancers (Basel). 2021. PMID: 34885154 Free PMC article.

2

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Mao Y, et al. Among authors: eissler n. Clin Cancer Res. 2016 Aug 1;22(15):3849-59. doi: 10.1158/1078-0432.CCR-15-1912. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957560

3

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.

Eissler N, Mao Y, Brodin D, Reuterswärd P, Andersson Svahn H, Johnsen JI, Kiessling R, Kogner P. Eissler N, et al. Oncoimmunology. 2016 Sep 9;5(12):e1232222. doi: 10.1080/2162402X.2016.1232222. eCollection 2016. Oncoimmunology. 2016. PMID: 28123870 Free PMC article.

4

Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.

Kock A, Larsson K, Bergqvist F, Eissler N, Elfman LHM, Raouf J, Korotkova M, Johnsen JI, Jakobsson PJ, Kogner P. Kock A, et al. Among authors: eissler n. EBioMedicine. 2018 Jun;32:84-92. doi: 10.1016/j.ebiom.2018.05.008. Epub 2018 May 24. EBioMedicine. 2018. PMID: 29804818 Free PMC article.

5

Body surface area-based omega-3 fatty acids supplementation strongly correlates to blood concentrations in children.

Ljungblad L, Gleissman H, Hedberg G, Wickström M, Eissler N, Pickova J, Johnsen JI, Tedroff K, Strandvik B, Kogner P. Ljungblad L, et al. Among authors: eissler n. Prostaglandins Leukot Essent Fatty Acids. 2021 Jun;169:102285. doi: 10.1016/j.plefa.2021.102285. Epub 2021 Apr 24. Prostaglandins Leukot Essent Fatty Acids. 2021. PMID: 33964665 Free article. Clinical Trial.

6

The role of immune semaphorins in cancer progression.

Eissler N, Rolny C. Eissler N, et al. Exp Cell Res. 2013 Jul 1;319(11):1635-43. doi: 10.1016/j.yexcr.2013.04.016. Epub 2013 May 18. Exp Cell Res. 2013. PMID: 23693019 Review. No abstract available.

7

Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.

Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Eissler N, et al. Cancer Res. 2012 Aug 15;72(16):3958-66. doi: 10.1158/0008-5472.CAN-12-0146. Epub 2012 Jun 28. Cancer Res. 2012. PMID: 22745368

8

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.

Ruf P, Schäfer B, Eissler N, Mocikat R, Hess J, Plöscher M, Wosch S, Suckstorff I, Zehetmeier C, Lindhofer H. Ruf P, et al. Among authors: eissler n. J Transl Med. 2012 Nov 7;10:219. doi: 10.1186/1479-5876-10-219. J Transl Med. 2012. PMID: 23134699 Free PMC article.

9

Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.

Eissler N, Mysliwietz J, Deppisch N, Ruf P, Lindhofer H, Mocikat R. Eissler N, et al. Mol Med. 2013 Apr 30;19(1):54-61. doi: 10.2119/molmed.2012.00140. Mol Med. 2013. PMID: 23552725 Free PMC article.

10

Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery.

Deppisch N, Ruf P, Eissler N, Neff F, Buhmann R, Lindhofer H, Mocikat R. Deppisch N, et al. Among authors: eissler n. Mol Cancer Ther. 2015 Aug;14(8):1877-83. doi: 10.1158/1535-7163.MCT-15-0156. Epub 2015 Jun 10. Mol Cancer Ther. 2015. PMID: 26063765

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page